Chemokines as Therapeutic Targets in Cardiovascular Disease The Road Behind, The Road Ahead

Heidi Noels, Christian Weber, Rory R. Koenen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

47 Citations (Web of Science)

Abstract

With the incidence and impact of atherosclerotic cardiovascular disease and its clinical manifestations still rising, therapeutic options that target the causal mechanisms of this disorder are highly desired. Since the CANTOS trial (Canakinumab Antiinflammatory Thrombosis Outcome Study) has demonstrated that lowering inflammation can be beneficial, focusing on mechanisms underlying inflammation, for example, leukocyte recruitment, is feasible. Being key orchestrators of leukocyte trafficking, chemokines have not lost their attractiveness as therapeutic targets, despite the difficult road to drug approval thus far. Still, innovative therapeutic approaches are being developed, paving the road towards the first chemokine-based therapeutic against inflammation. In this overview, recent developments for chemokines and for the chemokine-like factor MIF (macrophage migration inhibitory factor) will be discussed.

Original languageEnglish
Pages (from-to)583-592
Number of pages10
JournalArteriosclerosis Thrombosis and Vascular Biology
Volume39
Issue number4
DOIs
Publication statusPublished - Apr 2019

Keywords

  • atherosclerosis
  • bone marrow
  • cardiovascular disease
  • chemokines
  • myocardial infarction
  • MIGRATION-INHIBITORY FACTOR
  • CELL-DERIVED FACTOR-1-ALPHA
  • LIMITS ATHEROSCLEROSIS
  • INDEPENDENT PREDICTOR
  • PLATELET ACTIVATION
  • REPERFUSION INJURY
  • VASCULAR INJURY
  • CROSS-TALK
  • FACTOR-I
  • RECEPTOR

Cite this